Tardive Dyskinesia
A condition affecting the nervous system, often caused by long-term use of some psychiatric drugs.
Tardive dyskinesia is caused by long-term use of neuroleptic drugs, which are used to treat psychiatric conditions.
Tardive dyskinesia causes repetitive, involuntary movements, such as grimacing and eye blinking.
Stopping or tapering drugs that may be contributing to involuntary repetitive movements can help. In rare cases, botulinum toxin, deep brain stimulation, or medications can help.
Cluster Number:
Wiki Number: PW216
Diagnosis: Tardive Dyskinesia
US Patients: 30% of those taking antipsychotic medicines
World Patients:
Sex Ratio: M;F+
Age Onset: elderly
Brain Area:
Symptoms: involuntary, repetitive body movements: rapid-jerking or slow-writhing; grimacing, smacking lips, sticking out tongue, eye-blinking
Progression: walking is difficult or impossible due to excess leg movement
Causes: reactions to narcoleptic drugs; reactions to long-term-use of dopamine-receptor-blocking medications; antipsychotics
Medications: supersensitivity to dopamine becomes in the nigrostriatal pathway;discontinuing the narcoleptics helps; valbenazing, etc.
Therapies: No therapies listed; newer antipsychotic drugs cause less dyskinesia than the first generation of antipsychotic drugs did.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Upregulation of heat-shock protein HSP-70 and glutamate transporter-1/glutamine synthetase in the striatum and hippocampus in haloperidol-induced dopamine-supersensitivity-state ratsby Makoto Kimura on October 15, 2021
CONCLUSIONS: These results suggest that the DSS rats experienced striatal neuronal damage and indicate that a HAL-induced upregulation of HSP-70 and the GLT-1/GS system in the CA3 may be involved in the development of DSS. It remains unknown why the non-DSS rats did not suffer neuronal damage. In view of the need for therapeutic strategies for treatment-resistant schizophrenia, dopamine supersensitivity psychosis, and tardive dyskinesia, further investigations of our findings are warranted.
- Diagnostic and Treatment Fundamentals for Tardive Dyskinesiaby Christoph U Correll on October 13, 2021
Tardive dyskinesia (TD) consists of involuntary movements of the tongue, lips, face, trunk, and extremities that occur in patients treated long-term with dopamine antagonist medications. TD can be associated with significant functional impairment and be socially stigmatizing. TD, once established, has proved to be often irreversible and remains a significant treatment issue. An accurate and early diagnosis of TD is crucial because the risk of permanence increases over time. Clinicians should be...
- Prevalence, clinical correlates and risk factors associated with Tardive Dyskinesia in Chinese patients with schizophreniaby Kadir Uludag on October 12, 2021
Tardive Dyskinesia (TD) is a serious, nonrhythmic and iatrogenic movement disorder, and is a common comorbidity in patients with schizophrenia (SZ). The main goal of this study was to investigate the prevalence, clinical correlates, and risk factors of TD in Chinese patients with chronic SZ, which has not been fully studied. This study adopted a cross-sectional design. A total of 901 Chinese inpatients with SZ were recruited between 2008 and 2011. We used the Abnormal Involuntary Movement Scale...
- Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trialby Joseph Jankovic on October 5, 2021
CONCLUSIONS AND RELEVANCE: In this study of deutetrabenazine in children and adolescents with Tourette syndrome, the primary efficacy end point was not met. No new safety signals were identified. These results may be informative for future studies of treatments for tics in Tourette syndrome.